Grants for Public Housing Authorities

This program provides essential funding for energy-efficient home improvements to help low-income households in Pennsylvania reduce their energy costs and improve their living conditions.

The 2024-25 Physical and Digital Infrastructure Security Grant Program for Health Care Practitioners, offered by the California Governor’s Office of Emergency Services (Cal OES), aims to enhance physical facility and digital security for healthcare practitioners. This initiative aligns with a broader mission to safeguard healthcare services, particularly those related to abortion and reproductive health, which may be vulnerable to violence and vandalism. The program's core purpose is to mitigate security risks, ensuring uninterrupted and safe access to essential healthcare services for communities across California. The primary beneficiaries of this grant are currently licensed healthcare practitioners located in California who provide abortion-related services (or referrals) and reproductive health care services. This includes medical doctors, osteopathic doctors, licensed midwives, certified nurse-midwives, nurse practitioners, registered nurses, licensed vocational nurses, and physician assistants. A key impact goal is to create a more secure environment for these practitioners and their patients, thereby preserving access to critical reproductive health services. The program prioritizes security enhancements to protect against physical and digital threats. Eligible applicants must demonstrate that they provide abortion-related and reproductive health care services and are located in California. Health Care Practitioners who received an award from the FY 2022-23 DP Program are also eligible to reapply. The focus is on proactive measures to prevent violence and vandalism, fostering a safe operational space for healthcare providers. Expected outcomes include a measurable increase in the security infrastructure of participating healthcare facilities, both physically and digitally. The program anticipates that enhanced security will reduce incidents of violence and vandalism, leading to improved access to and continuity of abortion-related and reproductive health care services. With a total of $3 million available and individual grants up to $150,000, the program intends to achieve a widespread impact across California. The grant performance period runs from September 1, 2024, through December 31, 2026, allowing for significant improvements in the security landscape for these vital healthcare providers.

Under the broader Program Enhancement Projects for Adult Education, Section 225 targets corrections education and education for other institutionalized individuals in Connecticut. This initiative seeks to provide educational services to those likely to leave correctional institutions within five years, aiming to enhance their literacy, employment, and reintegration prospects. It emphasizes the importance of basic skills and literacy for effective societal participation. Funded through the Workforce Innovation and Opportunity Act (WIOA), the project promotes collaboration to meet the educational needs of this specific population, with a commitment to multi-year funding that spans from fiscal year 2025 to 2028. Grant renewed every year. It will be a 4-year program ( last application probably around May 2027)

Under the broader Program Enhancement Projects for Adult Education, Section 243 focuses on Integrated English Literacy and Civics Education (IELCE). This program supports English language learners in improving their literacy and understanding of American civics, aiming for better integration, employment, and educational opportunities. Eligible providers are encouraged to propose projects that combine IELCE educational services with integrated education and training (IET), reflecting the Workforce Innovation and Opportunity Act’s (WIOA) objectives. This funding opportunity, spanning fiscal years 2025 through 2028, promotes collaborations to fulfill the educational needs of English language learners in Connecticut. Grant renewed every year. It will be a 4-year program ( last application probably around May 2027)

The Program Enhancement Project for Adult Education, as part of the AEFLA Section 231 Comprehensive Adult Education Services, aims to expand and enhance educational programs for adults in Connecticut. With an emphasis on improving basic skills and literacy, the project facilitates effective participation in society and the workforce. It supports a variety of activities including adult literacy, workplace education, family literacy, and English language acquisition, among others. This initiative, funded through the Workforce Innovation and Opportunity Act (WIOA), encourages collaborations to avoid service duplication, address local needs, and ensure seamless educational transitions. The project is open for proposals from eligible agencies with the intent to award multi-year grants, ensuring sustained impact from fiscal year 2025 through 2028. Grant renewed every year. It will be a 4-year program ( last application probably around May 2027)

The purpose of this Notice Of Funding Opportunity (NOFO) is to solicit applications on the optimization and characterization of technologies and assays with the potential for utilization and adoption in regulatory submissions of genome editing therapeutics. The NIH Somatic Cell Genome Editing (SCGE) Program is funded through the NIH Common Fund, which supports cross-cutting programs that are expected to have exceptionally high impact. All Common Fund initiatives invite investigators to develop bold and innovative approaches to address problems that may seem intractable or to seize new opportunities that offer the potential for transformation of research processes. The simplicity and broad applicability of targeted and programmable genome editing approaches, including but not limited to those based on CRISPR-Cas9, raise the possibility of a fundamentally new way to treat a variety of genetic diseases. However, many challenges need to be overcome before such techniques could be widely used in the clinic. To maximize the potential of genome editing technology, the SGCE program was developed to accelerate the translation of genome editing technology into clinical applications. Based on input received from stakeholders from academia, industry, and regulatory agencies, as well as the substantial progress in the field of genome editing since the launch of the first five-year phase of the SCGE program, the second five-year phase of SCGE will focus on translating and accelerating safe and effective somatic cell genome editing therapeutics into the clinic. Specifically, SCGE Phase 2 will support the following initiatives: 1) Technologies and Assays for Therapeutic Genome Editing INDs; 2) IND-enabling Studies of Somatic Genome Editing Therapeutic Leads; 3) IND-enabling and Platform Clinical Trials of Somatic Genome Editing for Multiple Diseases and 4) Somatic Cell Genome Editing Translational Coordination and Dissemination Center (TCDC). The SCGE Program will involve collaborative research by a consortium of award recipients with differing expertise to develop, optimize and demonstrate improved candidate genome editing therapeutics as treatments for human disease. Recipients from all four SCGE program components will form a consortium, governed by a steering committee of investigators and NIH staff that will develop consensus policies and procedures for Consortium-wide activities such as data and resource sharing. Collectively, these initiatives are intended to substantially expand the number of genetic diseases treated by in vivo genome editing, ultimately allowing this technology to achieve its potential as a therapeutic platform to treat genetic disease. Program Formation and Governance The awards funded under this NOFO will be cooperative agreements (see Section VI.2. Cooperative Agreement Terms and Conditions of Award). Close interactions among the recipients and NIH will be required to maintain this complex program. The whole SCGE Program governance will rest with the SCGE Program Steering Committee in collaboration with NIH Program Officials, with advice from Program Consultants providing critical scientific and managerial insights, and subject to oversight by the NIH SCGE Working Group. The NIH SCGE Working Group consists of NIH Programmatic Staff from multiple Institutes and Centers of the NIH as well as the Office of the Director. This group will be primarily responsible for the stewardship of the SCGE Program. The SCGE Working Group is co-chaired by the Director of the National Center for Advancing Translational Sciences (NCATS) and the Director of the National Institute for Neurological Disorders and Stroke (NINDS). It reports to the Directors of the Office of Strategic Coordination/Common Fund and the Division of Program Coordination, Planning, and Strategic Initiatives for final funding decisions. Research Objectives The purpose of this 3-year U01 NOFO is to support the optimization and evaluation of IND-enabling technologies and assays to help accelerate the clinical development and evaluation of novel somatic cell genome editing therapeutics to treat a broad array of rare and common diseases. Examples of technologies and assays that would be responsive to this NOFO include those for Chemistry, Manufacturing and Controls (CMC), potency, pharmacology/toxicity, detection and measurement of on/off-target effects, immune responses, and cell tracking studies. Applicants should have an IND-enabling technology or assay to be optimized, with supportive preliminary data, at the time of submission. Projects should focus on further development and rigorous characterization of the technology and/or assay for utilization and adoption in regulatory submissions. This NOFO is intended to bring assays to the point where they could be integrated with future clinical trials/studies. Research Scope This program will support the optimization, refinement, and establishment of acceptability criteria of technologies and assays that will provide data on the efficacy and safety of somatic cell genome editing technologies and delivery systems in future regulatory submissions. In Investigational New Drug Applications (INDs) submitted to the U.S. Food and Drug Administration (FDA), sufficient CMC information should be provided to assure safety, identity, quality, purity, and strength (including potency) of the investigational product entering clinical trials. CMC activities include the establishment of manufacturing processes and product characteristics, as well as defining product testing methods to ensure that the product is safe, effective, and consistent between batches. To guide the CMC development plan, it is important to establish the Critical Quality Attributes (CQAs), a set of criteria to which a drug product should conform to be considered acceptable for its intended use. Establishing acceptable CQAs for genome editing therapeutics can be challenging due to the biological complexity of the products. Nevertheless, the risk associated with genome editing therapies can be reduced by developing appropriate analytical procedures and assays to help define suitable CQAs and ensure high-quality clinical products that meet the quality requirements for nonclinical and clinical trial materials. Process control techniques developed for protein drug production are not always applicable to cell and gene therapies. While a few in vivo somatic cell genome editing therapeutics have entered the clinic targeting the liver and eye, a comprehensive suite of technologies and assays to help define the CQAs of the genome editing product(s) have yet to be generated. Some examples of CMC challenges during the development of genome editing products include suitable potency assays to demonstrate relevant biological activity and to help determine dosage, pertinent assays to inform editing-related immunogenicity, safety and efficacy, manufacturing procedures suitable for scale-up for a multifaceted product, and other optimized bioanalytical assays to fulfill CMC-related activities. A combination of assays may be required when a single assay may not provide adequate CMC data due to a complex mechanism of action or multiple activities of a preliminary therapeutic agent. To support the clinical advancement and regulatory approval of the ever-increasing number of genome editing therapeutics, there is a need for appropriate fit-for-purpose CMC and analytical methodologies to be optimized and qualified for eventual implementation into genome editing therapeutic programs as these programs transition from research into clinical stages. Also in 2023, the FDA Modernization Act 2.0 permits the utilization of new approach methodologies (NAMs) to animal testing, including non-animal or human biology-based test methods, such as cell-based assays, microphysiological systems, or bioprinted or computer models to predict drug toxicity, metabolism, and other absorption, distribution, metabolism, and excretion (ADME) properties. NAMs can now be used to seek FDA exemptions for assessing drug safety and effectiveness during the preclinical phase. Some applicable assays have been developed by investigators in academic laboratories or small biotechnical companies for research purposes but require adaptation and/or comprehensive analysis to meet regulatory requirements during the review of clinical products. Applications responsive to this NOFO will fill this gap as these technologies and assays are critical during preclinical development and the manufacturing process, and would impact product quality, safety and efficacy during clinical application. Successful assays and associated protocols will be shared with the broader community via the Translational Coordination and Dissemination Center (TCDC) and SCGE Toolkit that will be the primary output of this collaborative Common Fund-sponsored program. Examples of product and process characterization assays supported by this NOFO include, but are not limited to: Technologies that enable more informative assessment of patient adaptive and/or innate immune (immunogenicity) responses to genome editors and vectors during clinical trials, including the presence or development of anti-drug antibodies, potential biological consequences, and whether those responses change over time or in response to redosing New approach methodologies that complement traditional animal research, including microphysiological systems, organoids, and other 3- dimensional cell models, that recapitulate critical aspects of normal human physiology and provide quantifiable and predictive measurements of genome editing effects Computer-based technologies, for example artificial intelligence or machine learning, for generating predictive models of individual or population-based biological response(s) to genome editing-based intervention Technologies to detect on and off-target editing in gene-edited animals (or humans) in a non-invasive manner, including but not limited to the use of cell-free DNA obtained from blood or other tissue compartments that can be readily accessed non-invasively (e.g. saliva, exhaled breath condensate, urine, stool) Methods to assess or predict the potential clinical impact of undesired off-target effects, including but not limited to cytotoxicity, genotoxicity, mutagenicity and tumorigenicity potential In vitro and in vivo assays for clinically relevant evaluation of the pharmacokinetic and pharmacodynamic properties of a genome delivery or editing reagent, including durability of editing, bioavailability, bioactivity, cell/tissue specificity, and/or dose-prediction in clinical trials Potency assays to assess specificity and sensitivity measurements of the functionality and efficiency of genome editing product, including vector infectivity and identity, editor activity, and other parameters as appropriate Process development technologies for scale-up and cGMP manufacturing of genome editing products Bioanalytical methods for final product identity and potential contamination Technologies for tracking and monitoring of genome editing therapies in vivo, which may include amongst others, in utero therapeutic products Applications addressing the following topics will be deemed non-responsive and will not be reviewed: Exploratory research for new technology development that lack supporting unpublished and/or preliminary data Assays that are not applicable to genome editing INDs Discovery or development of new genome editing therapeutic products Assays/technologies for non-somatic cell editing Projects proposing clinical trials Technologies that can be broadly applicable to more than one genome editing therapeutic product and/or indication are encouraged Funds from the NIH will be made available through the U01 cooperative agreement award mechanism. Awards will be up to 3 years in duration and will include milestones to evaluate progress. During the initial two years of funding, it is expected that investigators will complete the necessary studies to establish an assay profile and performance criteria (Accuracy [Relative], Analytical Measurement Range, Parallelism, Precision, Selectivity, Specificity, and Stability, as applicable) of sufficient quality for the likely utilization of the technology or assay to support IND-submission of genome editing therapeutic products. As part of the NIH SCGE Consortium, Consortium-generated animal and/or human samples from genome-editing therapeutic studies are expected to become available, and applicants are encouraged to collaborate with other SCGE Consortium members to help evaluate the utility and performance of the assay(s). It is anticipated that in the remainder of the award period, projects will continue to perform assay optimization and further define the analytical parameters using relevant samples, including samples from other consortium members as scientifically appropriate. NIH's Interest in Diversity Every facet of the United States scientific research enterprise—from basic laboratory research to clinical and translational research to policy formation–requires superior intellect, creativity and a wide range of skill sets and viewpoints. NIH’s ability to help ensure that the nation remains a global leader in scientific discovery and innovation is dependent upon a pool of highly talented scientists from diverse backgrounds who will help to further NIH's mission. Research shows that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogenous teams. Scientists and trainees from diverse backgrounds and life experiences bring different perspectives, creativity, and individual enterprise to address complex scientific problems. There are many benefits that flow from a diverse NIH-supported scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved or health disparity populations participate in, and benefit from health research, and enhancing public trust. NIH encourages applicants to include a diverse group of scientists in their research programs, including individuals from underrepresented backgrounds (see NOT-OD-20-031, Notice of NIH’s Interest in Diversity and NOT-OD-22-019, Reminder: Notice of NIH’s Encouragement of Applications Supporting Individuals from Underrepresented Ethnic and Racial Groups as well as Individuals with Disabilities). See Section VIII. Other Information for award authorities and regulations.

This funding opportunity provides financial support to research institutions for developing interdisciplinary centers focused on improving mental health and HIV/AIDS outcomes through innovative studies and community engagement.

Notice of Funding Opportunity summary:The United States Agency for International Development (USAID) is seeking applications for aCooperative Agreement from qualified entities to implement the Urban Health Activity. Eligibilityfor this award is not restricted.USAID intends to make an award to the applicant who best meets the objectives of this fundingopportunity based on the merit review criteria described in SECTION E of this Notice of FundingOpportunity (NOFO), subject to a risk assessment. The applicant receiving an award will be theRecipient. Eligible parties interested in submitting an application are encouraged to read thisNOFO thoroughly to understand the type of program sought, application submissionrequirements, and selection process.Activity short summary:USAID/Uganda plans to award a five-year Cooperative Agreement to enhance health systemresilience and improve the survival and well-being of the residents of Kampala city, Mukono, andWakiso districts (hereafter referred to as the Target Districts) (the Activity). The Activity willstrengthen public and private health systems at the facility and community levels to deliverresponsive, timely, evidence-based, quality services. The Activity will strengthen maternal,newborn, and child health (MNCH); malaria; family planning (FP) / reproductive health (RH);nutrition; and Global Health Security (GHS) services in the Target Districts.

Notice of Funding Opportunity SummaryThe Natural Resources Conservation Service (NRCS) is directing resources toward climate-smart agriculture and forestry (CSAF) conservation practices, including those for energy efficiency. NRCS is providing funding for a partnership to provide technical assistance to NRCS and producers on energy practices. Information related to NRCS CSAF practices can be found at the following web address: https://www.nrcs.usda.gov/sites/default/files/2023-10/NRCS-CSAF-Mitigation-Activities-List.pdf.A total of up to $1,500,000 is available in fiscal year 2024. All agreements will be five years in duration. Additional funds may be added to agreement in later years as funds become available. Total funding is dependent on the Federal Budget and technical workload in Ohio. For new users of Grants.gov, see Section D. of the full Notice of Funding Opportunity for information about steps required before submitting an application via Grants.gov.Key DatesApplicants must submit their applications via Grants.gov by 11:59 pm Eastern Time on May 22, 2024. For technical issues with Grants.gov, contact Grants.gov Applicant Support at 1-800-518-4726 or support@grants.gov. Awarding agency staff cannot support applicants regarding Grants.gov accounts.For inquiries specific to the content of the NFO requirements, contact the federal awarding agency contact (section G of this NFO). Please limit questions to those regarding specific information contained in this NFO (such as dates, page numbers, clarification of discrepancies, etc.). Questions related to eligibility or the merits of a specific proposal will not be addressed. The agency anticipates making selections by June 22, 2024 and expects to execute awards by July 22, 2024. These dates are estimates and are subject to change.

This funding opportunity provides support for U.S.-based research centers focused on innovative studies at the intersection of mental health and HIV/AIDS, aiming to address health disparities and improve treatment and prevention strategies.

This funding opportunity provides financial support for projects that protect and restore fish and wildlife resources affected by water management activities in Colorado.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) intend to publish a Notice of Funding Opportunity (NOFO) to solicit applications for large single or multisite clinical trials within the mission area of the institute. The NOFO is expected to be published in Spring 2024 with an expected application due date in Summer 2024. Only New, Resubmission and Revision applications will be eligible. This NOFO will utilize the UG3/UH3 phased cooperative agreement activity code. A UG3 milestone plan is required. Details of the planned NOFO are provided below.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development intends to publish a Notice of Funding Opportunity (NOFO) to invite applications for a Data Coordinating Center to support the work of the research projects funded under the Stillbirth Research Consortium described in the companion announcement NOT-HD-24-009. This Notice is being provided to allow potential applicants additional time to develop meaningful collaborations, interdisciplinary teams, and prepare responsive applications. The NOFO is expected to be published in Summer 2024 with an expected application due date in Fall 2024. This NOFO will utilize the UM2 activity code. Details of the planned NOFO are provided below.

The National Institute of Neurological Disorders and Stroke (NINDS), in collaboration with the National Institute of Mental Health (NIMH), intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications that propose the development and early stage validation of novel humanized small animal models and/or human cellular microphysiological systems for NeuroHIV preclinical research. The goal of this initiative is to promote a significant improvement in the translational relevance of NeuroHIV models, specifically in the context of chronic HIV infection of the central nervous system (CNS) in the modern antiretroviral therapy (ART) era under conditions of viral suppression. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in Summer 2024 with an expected application due date in Fall 2024. This NOFO will utilize the R61/R33 activity code. Details of the planned NOFO are provided below.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development intends to publish a Notice of Funding Opportunity (NOFO) to invite applications to establish integrated and collaborative Stillbirth Research Centers, as part of a new Stillbirth Research Consortium. The Centers will support cutting-edge basic, translational, clinical, and/or data sciences research and generate knowledge to fuel advancement of stillbirth-relevant research in the United States, with a particular emphasis on approaches that utilize an equity lens to identify ways to decrease the incidence of stillbirth in vulnerable populations. A Data Coordinating Center (described in the companion announcement NOT-HD-24-010) will support the work of the research projects funded under the Stillbirth Research Consortium. This Notice is being provided to allow potential applicants additional time to develop meaningful collaborations, interdisciplinary teams, and responsive applications. International collaboration is encouraged and allowable. The NOFO is expected to be published in Summer 2024 with an expected application due date in Winter 2024. This NOFO will utilize the UG1 activity code. Details of the planned NOFO are provided below.

The purpose of this Notice of Funding Opportunity (NOFO) is to support the development of clinical research platforms that will enable future clinical trials to determine whether combinations of HIV cure strategies can be effective when optimally tailored to the participants. The ultimate goal is for the results of such proof-of-concept clinical studies to inform the development and prioritization of more broad-based curative strategies that will be effective in all people living with HIV. This NOFO will support multidisciplinary teams to conduct coordinated basic and pre-clinical research to profile participants intact, rebound-competent HIV reservoirs and immunologic backgrounds and use that information to develop and test combinations of HIV curative approaches that are specifically tailored to those participants.

The NIH Directors Pioneer Award Program supports individual scientists of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. To support innovative and novel research across the vast NIH mission, individuals from diverse backgrounds (including those from underrepresented groups; see Notice of NIHs Interest in Diversity) and from the full spectrum of eligible institutions in all geographic locations are encouraged to apply to this Notice of Funding Opportunity. Applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Directors Pioneer Award is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund.

The purpose of this Notice is to alert the community that the National Institute of Neurological Disorders and Stroke (NINDS) plans to reissue initiativeRFA-NS-21-033 Materials to Enhance Training in Experimental Rigor (METER) with one receipt date. The program is designed to support the compilation and refinement of educational materials that will be incorporated into a new cutting-edge online resource that aims to promote awareness, understanding, and practice of fundamental principles of rigorous biomedical research for scientists in various career stages and learning environments. Awardees will collaborate with the established coordinating center, which is funded by the companionRFA-NS-21-009 Creating an Educational Nexus for Training in Experimental Rigor (CENTER). This coordinating center (CENTER) is responsible for organizing the initiative, building the final web-based platform, harmonizing the educational units, and producing digital elements (e.g., videos, graphics, interactive components) that are beyond the technical capabilities of METER awardees. This collaboration between CENTER and METER awardees will include activities to improve, finalize, evaluate, and disseminate the resulting educational units drafted by METER awardees. More information about the initiative, its current progress, and frequently asked questions can be found at https://www.ninds.nih.gov/current-research/trans-agency-activities/rigor-transparency/initiative-improve-education-principles-rigorous-research. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The overall objectives of the program have not changed; however, potential applicants can expect minor changes to improve the clarity of the previous announcement. The NOFO is expected to be published in Summer 2024 with an expected application due date in October 2024. This NOFO will utilize the UE5 activity code. Details of the planned NOFO are provided below.

This Notice of Funding Opportunity (NFO) is being released prior to appropriation and/or apportionment of funds for fiscal year 2024. Enactment of additional continuing resolutions or an appropriations act may affect the availability or level of funding for this program. The purpose of this NFO is to encourage and promote conservation planning and conservation practice implementation in urban, suburban, and other small-scale type agricultural operations. Emphasis will be placed on projects that establish new demonstration community gardens, or enhance and expand existing community agriculture projects. Proposals should seek to: 1. Provide conservation learning experiences to urban, suburban, and Tribal communities. 2. Address concerns regarding food deserts. 3. Advance Tribal food sovereignty. 4. Achieve positive and measurable natural resources conservation outcomes. For new users of Grants.gov, see Section D. of the full Notice of Funding Opportunity for information about steps required before submitting an application via Grants.gov. Key Dates Applicants must submit their applications via Grants.gov by 11:59 pm Eastern Time on May 22, 2024. For technical issues with Grants.gov, contact Grants.gov Applicant Support at 1-800-518-4726 or support@grants.gov. Awarding agency staff cannot support applicants regarding Grants.gov accounts. For inquiries specific to the content of the NFO requirements, contact the federal awarding agency contact (section G of this NFO). Please limit questions to those regarding specific information contained in this NFO (such as dates, page numbers, clarification of discrepancies, etc.). Questions related to eligibility or the merits of a specific proposal will not be addressed. The agency anticipates making selections by June 21, 2024 and expects to execute awards by September 1, 2024. These dates are estimates and are subject to change.

The National Institute of Neurological Disorders and Stroke (NINDS), intends to publish a reissue Notice of Funding Opportunity (NOFO) to solicit applications for innovative, interactive research to answer significant scientific questions that are important for the mission of NINDS, via a synergistic collaboration between outstanding scientists who might not otherwise collaborate. The program project grant is designed to support research in which the funding of several interdependent highly meritorious projects as a group offers significant scientific advantages over support of these same projects as individual research grants.. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in April 2024 with an expected application due dates in May and September 2024. NINDS will not have any receipt dates after September 2024, thus ending the program. This NOFO will utilize the P01 activity code. Details of the planned NOFO are provided below.